SEARCH

SEARCH BY CITATION

References

  • 1
    van Deventer SJ. Immunotherapy of Crohn's disease. Scand J Immunol 2000; 51: 1822.
  • 2
    Present DH. How to do without steroids in inflammatory bowel disease. Inflammatory Bowel Diseases 2000; 6: 4857.
  • 3
    Hommes DW, van Deventer SJ. Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease [In Process Citation]. Curr Opin Clin Nutr Metab Care 2000; 3: 1915.
  • 4
    van Deventer SJ. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease-the mechanisms of action of infliximab. Aliment Pharmacol Ther 1999; 13 (suppl 4): 38.
  • 5
    van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 12935.
  • 6
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398405.
  • 7
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 7619.
  • 8
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 9
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398405.
  • 10
    Feagan BG. Review article: economic issues in Crohn's disease—assessing the effects of new treatments on health-related quality of life. Aliment Pharmacol Ther 1999; 13 (suppl 4): 2937.
  • 11
    Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience [In Process Citation]. Am J Gastroenterol 2000; 95: 346977.
    Direct Link:
  • 12
    Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease [In Process Citation]. Am J Gastroenterol 2000; 95: 34907.
    Direct Link:
  • 13
    Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 43944.
  • 14
    Puchner TC, Kugathasan S, Kelly KJ, et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflammatory Bowel Diseases 2001; 7: 347.
  • 15
    Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594602.
  • 16
    Heller T, James SP, Drachenberg C, et al. Treatment of severe esophageal Crohn's disease with infliximab. Inflammatory Bowel Diseases 1999; 5: 27982.
  • 17
    Ventura SJ, Mosher WD, Curtin SC, et al. Highlights of trends in pregnancies and pregnancy rates by outcome: estimates for the United States, 1976-96. Natl Vital Stat Rep 1999; 47: 19.